PURPOSE: Malignant perivascular epithelioid cell tumor (PEComa) is a rare aggressive sarcoma, with no approved treatment. To our knowledge, this phase II, single-arm, registration trial is the first prospective clinical trial in this disease, investigating the safety and efficacy of the mammalian target of rapamycin inhibitor nab-sirolimus (AMPECT, NCT02494570). PATIENTS AND METHODS: Patients with malignant PEComa were treated with nab-sirolimus 100 mg/m2 intravenously once weekly for 2 weeks in 3-week cycles. The primary end point was objective response rate evaluated by independent radiology review. Key secondary end points included duration of response, progression-free survival, and safety. A key exploratory end point was tumor biomarker analysis. RESULTS: Thirty-four patients were treated (safety evaluable), and 31 were evaluable for efficacy. The overall response rate was 39% (12 of 31; 95% CI, 22 to 58) with one complete and 11 partial responses, 52% (16 of 31) of patients had stable disease, and 10% (3 of 31) had progressive disease. Responses were of rapid onset (67% by week 6) and durable. Median duration of response was not reached after a median follow-up for response of 2.5 years, with 7 of 12 responders with treatment ongoing (range, 5.6-47.2+ months). Twenty-five of 31 patients had tumor mutation profiling: 8 of 9 (89%) patients with a TSC2 mutation achieved a confirmed response versus 2 of 16 (13%) without TSC2 mutation (P < .001). The median progression-free survival was 10.6 months (95% CI, 5.5 months to not reached), and the median overall survival was 40.8 months (95% CI, 22.2 months to not reached). Most treatment-related adverse events were grade 1 or 2 and were manageable for long-term treatment. No grade ≥ 4 treatment-related events occurred. CONCLUSION: nab-Sirolimus is active in patients with malignant PEComa. The response rate, durability of response, disease control rate, and safety profile support that nab-sirolimus represents an important new treatment option for this disease.
PURPOSE: Malignant perivascular epithelioid cell tumor (PEComa) is a rare aggressive sarcoma, with no approved treatment. To our knowledge, this phase II, single-arm, registration trial is the first prospective clinical trial in this disease, investigating the safety and efficacy of the mammalian target of rapamycin inhibitor nab-sirolimus (AMPECT, NCT02494570). PATIENTS AND METHODS: Patients with malignant PEComa were treated with nab-sirolimus 100 mg/m2 intravenously once weekly for 2 weeks in 3-week cycles. The primary end point was objective response rate evaluated by independent radiology review. Key secondary end points included duration of response, progression-free survival, and safety. A key exploratory end point was tumor biomarker analysis. RESULTS: Thirty-four patients were treated (safety evaluable), and 31 were evaluable for efficacy. The overall response rate was 39% (12 of 31; 95% CI, 22 to 58) with one complete and 11 partial responses, 52% (16 of 31) of patients had stable disease, and 10% (3 of 31) had progressive disease. Responses were of rapid onset (67% by week 6) and durable. Median duration of response was not reached after a median follow-up for response of 2.5 years, with 7 of 12 responders with treatment ongoing (range, 5.6-47.2+ months). Twenty-five of 31 patients had tumor mutation profiling: 8 of 9 (89%) patients with a TSC2 mutation achieved a confirmed response versus 2 of 16 (13%) without TSC2 mutation (P < .001). The median progression-free survival was 10.6 months (95% CI, 5.5 months to not reached), and the median overall survival was 40.8 months (95% CI, 22.2 months to not reached). Most treatment-related adverse events were grade 1 or 2 and were manageable for long-term treatment. No grade ≥ 4 treatment-related events occurred. CONCLUSION: nab-Sirolimus is active in patients with malignant PEComa. The response rate, durability of response, disease control rate, and safety profile support that nab-sirolimus represents an important new treatment option for this disease.
Authors: A Italiano; C Delcambre; I Hostein; A L Cazeau; M Marty; A Avril; J-M Coindre; B Bui Journal: Ann Oncol Date: 2010-03-09 Impact factor: 32.976
Authors: Charlotte Benson; Joanna Vitfell-Rasmussen; Marco Maruzzo; Cyril Fisher; Nina Tunariu; Scott Mitchell; Omar Al-Muderis; Khin Thway; James Larkin; Ian Judson Journal: Anticancer Res Date: 2014-07 Impact factor: 2.480
Authors: Fleur Weeber; Marco J Koudijs; Marlous Hoogstraat; Nicolle J M Besselink; Stef VAN Lieshout; Isaac J Nijman; Edwin Cuppen; G Johan Offerhaus; Emile E Voest Journal: Anticancer Res Date: 2015-06 Impact factor: 2.480
Authors: Mark A Socinski; Igor Bondarenko; Nina A Karaseva; Anatoly M Makhson; Igor Vynnychenko; Isamu Okamoto; Jeremy K Hon; Vera Hirsh; Paul Bhar; Hui Zhang; Jose L Iglesias; Markus F Renschler Journal: J Clin Oncol Date: 2012-04-30 Impact factor: 44.544
Authors: Roberta Sanfilippo; Robin L Jones; Jean-Yves Blay; Axel Le Cesne; Salvatore Provenzano; Georgios Antoniou; Olivier Mir; Giovanni Fucà; Elena Fumagalli; Rossella Bertulli; Silvia Stacchiotti; Mehdi Brahmi; Federica Grosso; Armelle Dufresne; Nadia Hindi; Marta Sbaraglia; Alessandro Gronchi; Paola Collini; Angelo P Dei Tos; Paolo G Casali Journal: Clin Cancer Res Date: 2019-06-19 Impact factor: 12.531
Authors: Christopher W Ryan; Ofer Merimsky; Mark Agulnik; Jean-Yves Blay; Scott M Schuetze; Brian A Van Tine; Robin L Jones; Anthony D Elias; Edwin Choy; Thierry Alcindor; Vicki L Keedy; Damon R Reed; Robert N Taub; Antoine Italiano; Xavier Garcia Del Muro; Ian R Judson; Jill Y Buck; Francois Lebel; Jonathan J Lewis; Robert G Maki; Patrick Schöffski Journal: J Clin Oncol Date: 2016-09-30 Impact factor: 44.544
Authors: Jeremy M Quintana; David Arboleda; Huiyu Hu; Ella Scott; Gaurav Luthria; Sara Pai; Sareh Parangi; Ralph Weissleder; Miles A Miller Journal: Bioconjug Chem Date: 2022-07-14 Impact factor: 6.069